Inflammatory myofibroblastic tumors harbor multiple potentially actionable Kinase fusions

Cancer Discovery

Volumn 4, Issue 8, 2014, Pages 889-895

  Lovly, Christine M ^a   Gupta, Abha ^b   Lipson, Doron ^c   Otto, Geoff ^c   Brennan, Tina ^c   Chung, Catherine T ^b   Borinstein, Scott C ^a   Ross, Jeffrey S ^c,d   Stephens, Philip J ^c   Miller, Vincent A ^c   Coffin, Cheryl M ^e  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c FOUNDATION MEDICINE   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; AXITINIB; BINDING PROTEIN; CLATHRIN HEAVY CHAIN; CORTICOSTEROID; CRIZOTINIB; CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IALPHA; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN 4; FIBRONECTIN; HEMOGLOBIN; INDOMETACIN; LAMIN A; METHOTREXATE; NAPROXEN; NAVELBINE; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; RAN PROTEIN; REGORAFENIB; SORAFENIB; SUNITINIB; TFG PROTEIN; TROPOMYOSIN; TRYPTOPHAN HYDROXYLASE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; ONCOPROTEIN; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; ROS1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CASE REPORT; CHILD; DNA SEQUENCE; ERYTHROCYTE SEDIMENTATION RATE; GENE FUSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEAN CORPUSCULAR VOLUME; MOLECULARLY TARGETED THERAPY; NEXT GENERATION SEQUENCING; PLASMA CELL GRANULOMA; PROTEIN EXPRESSION; QUALITY OF LIFE; SCHOOL CHILD; TUMOR BIOPSY; ANTAGONISTS AND INHIBITORS; GENETICS; INFLAMMATION; NEOPLASMS, MUSCLE TISSUE; PATHOLOGY;

BIOMARKERS, TUMOR; CHILD; HUMANS; INFLAMMATION; MALE; NEOPLASMS, MUSCLE TISSUE; ONCOGENE PROTEINS, FUSION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 84905491225     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0377     Document Type: Article

References (19)

1. Gleason BC, Hornick JL. Inflammatory myofibroblastic tumours: where are we now? J Clin Pathol 2008;61:428-37.
2. Tothova Z, Wagner AJ. Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors. Curr Opin Oncol 2012;24:409-13.
3. Coffin CM, Fletcher JA. Inflammatory myofibroblastic tumor. WHO Classification of Tumours of Soft Tissue and Bone. Lyon: IARC; 2013.
4. Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 2001;14:569-76.
5. Takeuchi K, Soda M, Togashi Y, Sugawara E, Hatano S, Asaka R, et al. Pulmonary inflammatory myofibroblastic tumor expressing a novel fusion, PPFIBP1-ALK: reappraisal of anti-ALK immunohistochemistry as a tool for novel ALK fusion identification. Clin Cancer Res 2011;17:3341-8.
6. Butrynski JE, D'Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, et al. Crizotinib in ALK-rearranged infl ammatory myofibroblastic tumor. N Engl J Med 2010;363:1727-33.
7. Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 2007;31:509-20.
8. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements defi ne a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-70.
9. Ou S, Bang YJ, Camidge DR, Riely GJ, Salgia R, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced ROS1rearranged non-small cell lung cancer (NSCLC). J Clin Oncol 2013; 31(suppl; abstr 8032).
10. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-4.
11. Vignot S, Frampton GM, Soria JC, Yelensky R, Commo F, Brambilla C, et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumor and metastases from patients with non-small-cell lung cancer. J Clin Oncol 2013;31:2167-72.
12. Drilon A, Wang L, Hasanovic A, Suehara Y, Lipson D, Stephens P, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013;3:630-5.
13. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
14. Mosse YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol 2013;14:472-80.
15. David M, Cross NC, Burgstaller S, Chase A, Curtis C, Dang R, et al. Durable responses to imatinib in patients with PDGFRB fusion genepositive and BCR-ABL-negative chronic myeloproliferative disorders. Blood 2007;109:61-4.
16. Ren H, Tan Z P, Zhu X, Crosby K, Haack H, Ren JM, et al. Identification of anaplastic lymphoma kinase as a potential therapeutic target in ovarian cancer. Cancer Res 2012;72:3312-23.
17. Doebele RC, Pilling AB, Aisner D, Kutateladze TG, Le AT, Weickhardt AJ, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012;18:1472-82.
18. Cross N C, Reiter A. Fibroblast growth factor receptor and plateletderived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 2008;119:199-206.
19. Davies K D, Doebele R C. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 2013;19:4040-5.